CN113801798B - Acidocella adephagia strain A50, extracellular polysaccharide produced by same and application thereof - Google Patents
Acidocella adephagia strain A50, extracellular polysaccharide produced by same and application thereof Download PDFInfo
- Publication number
- CN113801798B CN113801798B CN202110881679.XA CN202110881679A CN113801798B CN 113801798 B CN113801798 B CN 113801798B CN 202110881679 A CN202110881679 A CN 202110881679A CN 113801798 B CN113801798 B CN 113801798B
- Authority
- CN
- China
- Prior art keywords
- strain
- extracellular polysaccharide
- polysaccharide
- blastobotrys adeninivorans
- bile acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 44
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 44
- 241000501828 Acidocella Species 0.000 title claims description 4
- 150000004676 glycans Chemical class 0.000 title claims 3
- 239000003613 bile acid Substances 0.000 claims abstract description 27
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 23
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 5
- 230000000813 microbial effect Effects 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 6
- 229920002444 Exopolysaccharide Polymers 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 241000186063 Arthrobacter Species 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims 2
- 238000007796 conventional method Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 150000004804 polysaccharides Chemical class 0.000 abstract description 41
- 241001122767 Theaceae Species 0.000 abstract description 13
- 241000680806 Blastobotrys adeninivorans Species 0.000 abstract description 11
- 238000000855 fermentation Methods 0.000 abstract description 11
- 230000004151 fermentation Effects 0.000 abstract description 11
- 235000000346 sugar Nutrition 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 230000027455 binding Effects 0.000 abstract description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical group C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 abstract description 4
- 239000002253 acid Substances 0.000 abstract description 4
- 229920001284 acidic polysaccharide Polymers 0.000 abstract description 4
- 150000004805 acidic polysaccharides Chemical group 0.000 abstract description 4
- 238000004458 analytical method Methods 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 238000002329 infrared spectrum Methods 0.000 abstract description 4
- 238000002211 ultraviolet spectrum Methods 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 3
- 108020004707 nucleic acids Proteins 0.000 abstract description 3
- 150000007523 nucleic acids Chemical class 0.000 abstract description 3
- 102000039446 nucleic acids Human genes 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 230000000877 morphologic effect Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 235000013616 tea Nutrition 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 150000002772 monosaccharides Chemical class 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 238000005227 gel permeation chromatography Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 241000159601 Blastobotrys Species 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 241000589291 Acinetobacter Species 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- 241000223602 Alternaria alternata Species 0.000 description 1
- 241000269335 Ambystoma laterale x Ambystoma jeffersonianum Species 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241001205401 Aspergillus cristatus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 230000010784 Bile-acid Binding Activity Effects 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of microorganisms, and particularly relates to a Blastobotrys adeninivorans A strain and extracellular polysaccharide produced by the strain, and discloses the effect of extracellular polysaccharide in combination with bile acid. The strain of the invention was isolated from a Liupu tea sample of the pile fermentation process and identified as Blastobotrys adeninivorans by molecular and morphological analysis. The extracellular polysaccharide of the strain contains 78.08% of total sugar and 17.81% of uronic acid, and the ultraviolet spectrum shows that the extracellular polysaccharide is free of nucleic acid protein, the infrared spectrum shows that the extracellular polysaccharide is acidic polysaccharide and is sulfated polysaccharide, and the alpha-pyran ring and the furan ring exist at the same time. The extracellular polysaccharide has better bile acid binding effect in vitro, has half-inhibition concentration IC50 value of 64.325mg/ml, has potential blood lipid reducing capability, and has good application prospect in the aspects of preventing and treating hyperlipidemia and the like.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to a Blastobotrys adeninivorans A strain capable of producing extracellular polysaccharide and having a bile acid binding effect and application thereof.
Background
Hyperlipidemia refers to a condition characterized by an abnormally elevated level of one or more lipid components in the plasma (or serum). Atherosclerosis caused by this disorder is an important factor in the occurrence of cardiovascular diseases. Conversion to bile acids in the liver is the main way cholesterol is metabolized in the body. More than 95% of bile acid generated by the liver can be reabsorbed by human body, and the small part which is not absorbed can be discharged with feces. Bile acid binders can bind with bile acids in the small intestine to form insoluble complexes and be discharged outside the body, resulting in accelerated conversion of cholesterol in the liver or blood to bile acids, thereby exerting an effect of lowering cholesterol in the body.
Bile acid binders fall into two broad categories: anion exchange resins and dietary fiber polysaccharides. The administration of some dietary fiber polysaccharides such as oat and barley beta-glucan, pectin in fruit, guar gum, results in increased bile acid excretion in feces to 35% -65%. The microbial polysaccharide is widely used in various fields such as food and pharmacy because of low cost and easy production, and is not affected by seasons. However, compared to plant polysaccharides, there is less research on bile acid binding activity of microbial exopolysaccharides, which is detrimental to the development of microbial resources.
Liupu tea is considered as a healthy and health-preserving leisure drink, and Liupu tea polysaccharide has been studied to bind bile acid in blood. The special tea making process makes the formation of unique quality of Liupu tea not leave the action of microbe in the pile fermentation process. Studies have reported that exopolysaccharide of Eurotium cristatum is one of the active ingredients of Fuzhuan tea polysaccharide, and has lipid-lowering activity. However, no functional information has been reported about Blastobotrys adeninivorans exopolysaccharides in Liupu tea.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention provides the following technical scheme:
the invention provides a Blastobotrys adeninivorans A strain capable of producing extracellular polysaccharide and having a bile acid binding effect, wherein Blastobotrys adeninivorans A is preserved in China Center for Type Culture Collection (CCTCC) at the year 2021 and the month 04 and has the preservation number of CCTCC NO: M2021485.
The Blastobotrys adeninivorans strain belongs to the genus Blastobotrys of the family Trichomonasceae of the order Saccharomyces, of the order Saccharomyces.
(1) The A50 strain is obtained by fermenting tea leaves in the pile fermentation process of Liupu tea enterprises in Guangxi Zhuang nationality, chinese urban areas, and the identification result shows that the colony of the Alternaria alternata A50 on a PDA culture medium is white and dry, and is circular and opaque; cells were observed under the microscope to be round or quasi-round.
Further, the a50 strain produces extracellular polysaccharide in PDB medium. The fermentation liquor of the strain is subjected to centrifugation to collect supernatant, then 3 times of absolute ethyl alcohol with volume is added for precipitation twice, and the fermentation liquor is dried. Adding distilled water for dissolution, removing protein by Sevag method, adding three times of 95% ethanol, and centrifuging for precipitation. Dissolving the precipitate with distilled water, loading into dialysis bag with molecular weight cut-off of 8000Da-12000 and Da, and lyophilizing sugar solution to obtain EPS-A50.
The EPS-A50 had a composition of 78.08% total sugars, 17.81% uronic acid. The ultraviolet spectrum has no absorption peak at 260nm-280nm, indicating no nucleic acid or protein. Infrared spectrum indicates that the extracellular polysaccharide is an acidic polysaccharide and is a sulfated polysaccharide; the monosaccharide composition has mannose, with both an alpha-pyran ring and a furan ring. The molecular weight of EPS-A50 was 320.799kDa (26.28%), 26.618kDa (72.30%), 1.786kDa (1.42%), the monosaccharide composition consisting of Man, galA and Gal, the molar ratios being 0.99, respectively: 1.34:39.02.
furthermore, the extracellular polysaccharide has 23.81% -79.24% of in-vitro binding bile acid effect at the concentration of 10-110mg/mL, and the half-inhibitory concentration IC50 value is 64.325mg/mL. Therefore, the microbial agent can be applied to preparation of microbial agents, for example, can be used as a bile acid binding agent for reducing blood fat, and can be especially used for preparing drugs for preventing and/or treating hyperlipidemia.
The microbial agent can be prepared into preparations acceptable in foods, health-care products or medicines. The strain is from Liupu tea, so that the components are safe and reliable, and the applicability is strong.
Compared with the prior art, the invention has the following advantages: the strain has reliable source and safe components. And the microbial fermentation technology is adopted, so that the enlarged production is easy to realize. The extracellular polysaccharide produced by the strain has good effect of combining bile acid and strong applicability.
Drawings
FIG. 1 is a microscopic image of strain A50.
FIG. 2 is a diagram of the A50 strain neighbor-training algorithm system evolution tree.
FIG. 3 is an ultraviolet spectrum of EPS-A50.
FIG. 4 is an infrared spectrum of EPS-A50.
FIG. 5 is a graph showing the molecular weight of EPS-A50.
FIG. 6 is a diagram showing the monosaccharide composition of EPS-A50.
FIG. 7 is a graph showing the effect of EPS-A50 binding bile acids in vitro.
Detailed Description
The technical solutions of the present invention will be clearly and completely described in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1 Blastobotrys adeninivorans A50 isolation, cultivation and identification of Strain
1. Isolation and culture of strains
(1) Collecting bacterial colonies: 2g of fresh Liupu tea sample (collected place: fermented tea sample in pile fermentation process of Liupu tea enterprise in Guangxi Zhuang nationality, phoenix state) in pile fermentation process is taken, sheared by scissors, poured into a blue mouth bottle filled with 20mL of sterile water, and oscillated for 30min under the condition of 80r/min, so that microorganisms attached to the tea fall off.
(2) Colony purification: 1mL stock solutions of bacterial colonies are respectively diluted to 10 -1 、10 -2 、10 -3 、10 -4 、10 -5 、10 -6 Is absorbed by the bacteria suspension with gradient concentration200. Mu.L of the bacterial suspension was taken and poured into PDA and uniformly coated with a disposable coating rod. The culture was carried out in an incubator at 28℃for 2 to 3 days. After the bacterial colonies grow out of the coated culture dish, sorting by naked eyes, picking the colony edges of the strains with different forms, inoculating the colony edges to a PDA, and repeating the purification for more than 4 times until the colony becomes a single colony.
2. Morphological identification of strains
(1) The bacterial colony of the A50 strain on the PDA is white, dry, circular and opaque.
(2) And (3) observing by a microscope: as shown in FIG. 1, the cells are round or quasi-round.
3. Molecular characterization
(1) First 16S rRNA sequencing was performed: the single colony after purification was inoculated to PDA and cultured in an incubator at 28℃for 12 to 24 hours. Taking 50 mu L of sterilized resin solution in eight connecting tubes, picking up a small part of thalli by using a toothpick, placing the thalli in the eight connecting tubes and grinding for 1min. The eight-connecting tube is kept at the temperature of 100 ℃ in a metal bath for 10min, and the supernatant is obtained by centrifugation to obtain the template DNA. The template DNA fragments were amplified and sent to biosystems for sequencing. The sequence of 16S rRNA of the A50 strain is obtained and is shown as SEQ ID NO. 1.
(2) All the sequences of 16S rRNA from the species Acinetobacter adenivorum were collected in the EzTaxon database (http:// www.ezbiocloud.net/ezTaxon). All sequences were aligned and cut using software CLUSTAL_X, and the evolutionary tree was constructed using software MEGA X, with algorithms of neighbor-joining and Maximum-likelihood algorithms (Bootstrap: 1000 alternatives).
Phylogenetic analysis was performed using sequence alignment, and the results of the evolutionary tree are shown in FIG. 2. The results show that the A50 strain belongs to Blastobotrys, the closest strain is Blastobotrys adeninivorans, and is preserved, the A50 strain is preserved in China Center for Type Culture Collection (CCTCC) at the year 04 and the month 29 of 2021, and the preservation number is CCTCC NO: M2021485, and the preservation address is: university of martial arts in chinese.
Example 2 Blastobotrys adeninivoransA50 fermentation culture of Strain
1. Seed liquid culture
The strain is taken out of the freezing tube box according to the serial number, placed at room temperature for dissolution, inoculated to PDA, cultured for 24 hours at 28 ℃, then inoculated to select single bacterial colony to be inoculated to a YEPD liquid culture medium (20.0 g of peptone, 10.0g of yeast powder, 20.0g of glucose and 1000.0mL of distilled water), fermented for 18-24 hours at 28 ℃ and 120r/min, and the absorbance value of bacterial liquid at 600nm is regulated to be about 1.0, thus obtaining seed liquid.
2. Expansion culture
500mL Erlenmeyer flasks containing 250mL PDB were inoculated at a 5% inoculation rate and fermented at 28℃for 168 hours at 120 r/min.
Example 3 Blastobotrys adeninivoransA50 extraction, purification and component determination of extracellular polysaccharide EPS-A50 produced by Strain
1. Extracting and purifying
After fermentation, the fermentation broth is centrifuged at 6000r/min for 20min, three times of absolute ethyl alcohol is added, the sediment is deposited overnight in a refrigerator at 4 ℃, a certain volume of distilled water is added for remelting after the sediment is dried in the air, and then 3 times of 95% ethanol is added at 4 ℃ overnight. Collecting the precipitate, and air drying. Distilled water is added to dissolve and prepare 1% sugar solution, and protein is removed by Sevag method. Mixing n-butanol with distilled water in equal volume, and performing ultrasonic treatment for 10min to obtain water saturated n-butanol solution as the upper layer solution. 4 volumes of chloroform were added to the n-butanol solution to obtain Sevag reagent. One third of the volume of Sevag reagent was added to the sugar solution and stirred with a magnetic stirrer for 20min, poured into a separatory funnel and allowed to stand until a clear delamination was seen, and the lower organic reagent and the middle deformable proteins were removed. The upper layer was collected as a deproteinized sugar solution. The deproteinization operation was repeated until no milky precipitate was seen. The organic reagent was then removed by rotary evaporation at 60 ℃. Three volumes of 95% ethanol were added and the precipitate was collected by centrifugation at 4 ℃ overnight in a refrigerator. Dissolving the precipitate with distilled water, loading into dialysis bag with molecular weight cutoff of 8000Da-12000 Da, dialyzing in distilled water of 100 times volume, changing water every 4 hours, and dialyzing for 48 hr. After dialysis, the sugar solution was freeze-dried to give EPS-A50.
2. Component measurement
Methods for determining total sugar, uronic acid and protein content were slightly modified with reference to the literature. The results showed that EPS-A50 contained 78.08.+ -. 1.59% total sugar, 17.81.+ -. 1.21% uronic acid, and no protein.
Example 4 Blastobotrys adeninivorans A50 ultraviolet and Infrared Spectrometry analysis of extracellular polysaccharide EPS-A50 produced by the Strain
1. Ultraviolet spectrum
The extracellular polysaccharide sample was dissolved in distilled water and adjusted to an appropriate concentration, followed by scanning analysis with an ultraviolet spectrometer (Shimadzu corporation, UV 2501 PC) at a scanning wavelength in the range of 200nm to 400 nm. As shown in FIG. 3, EPS-A50 had no absorption peak at 260nm-280nm, indicating that it did not contain nucleic acid and protein.
2. Infrared spectrum
The extracellular polysaccharide sample 3mg and potassium bromide solid powder 270mg were weighed, mixed and ground until the sample particles were free of lens, and then pressed into uniform flakes by a tabletting machine. Scanning with Fourier transform infrared spectrometer (Fourier transform-infra-red, FT-IR) with a scanning range of 4000cm -1 -400cm -1 。
EPS-A50 as shown in FIG. 4 at 3407.47cm -1 The strong absorption peak at this point can be attributed to the stretching vibration peak of the O-H bond, indicating the presence of hydroxyl groups; 2933.45cm -1 The peak at this point is-CH on the sugar chain 2 Or the stretching vibration peak of the C-H bond of the-CH. The above is the characteristic absorption peak of polysaccharide. 1639.50cm -1 The peaks near where this is due to the presence of bound water. 1418.50cm -1 The peak may be the characteristic of carboxyl or carboxylate, indicating that the extracellular polysaccharide is an acidic polysaccharide, which is consistent with the determination of physicochemical index. Polysaccharide at 1239.15cm -1 There is an absorption peak, which is the stretching vibration peak of s=o, indicating a sulfated polysaccharide. 1100cm -1 -1010cm -1 There are 3 peaks representing pyran rings and 2 peaks representing furan rings. The results showed only 2 peaks for the polysaccharide, indicating a furan ring. EPS-A50 at 1079.18cm -1 The absorption peak of the ether bond C-O-C and the hydroxyl group of the pyran ring. Polysaccharide at 1021.13cm -1 The C-O stretching vibration peak is shown. 931.67cm -1 The peak indicates that mannose may be contained. At 890cm -1 And 812cm -1 No absorption peak (specific signal of beta configuration) at 850cm -1 The peak was left and right, indicating that the alpha-glycosidic bond was contained. EPS-A50 at 765.13cm -1 The absorption peak is caused by the symmetrical stretching vibration of the alpha-pyran ring.
The above results illustrate: the extracellular polysaccharide is acidic polysaccharide and is a sulfated polysaccharide, and the monosaccharide composition is mannose. EPS-A50 has both an alpha-pyran ring and a furan ring.
Example 5 Blastobotrys adeninivorans A50 detection of molecular weight and monosaccharide composition of extracellular polysaccharide EPS-A50 produced
1. Determination of molecular weight
The molecular weight of the extracellular polysaccharide was determined by gel permeation chromatography (Gel Permeation Chromatography, GPC). Extracellular polysaccharide and dextran standards (580, 29330, 10730, 31420, 63350, 143400, 280500, 841700, 2560000 and 7500000 Da) were dissolved in ultrapure water to prepare 1mg/mL solutions. Chromatographic conditions: waters GPC model 1515 equipped with a differential refractive detector, column: WATERS Ultrahydrogel 500column (7.8X100 mm), WATERS Ultrahydrogel 250column (7.8X100 mm) and WATERS Ultrahydrogel 120column (7.8X100 mm) are used in series. Mobile phase: ultrapure water; flow rate: 1.0mL/min; column temperature: 30 ℃; sample injection amount: 40. Mu.L.
As a result, FIG. 5 shows that FIG. 5 (a) is a standard curve of dextran standard, R 2 =0.9985 indicates a good linear range and a reliable method. FIG. 5 (b) is a GPC chart of EPS-A50, showing that the molecular weight of EPS-A50 is 320.799kDa (26.28%), 26.618kDa (72.30%), 1.786kDa (1.42%) by substituting the retention time into the standard curve.
2. Monosaccharide composition determination
Hydrolysis of polysaccharide: placing 0.0500g of extracellular polysaccharide powder into a hydrolysis tube, adding 1mL of HCl (3.0 mol/L), sealing, mixing, hydrolyzing at 110deg.C for 4-6 hr, cooling, adjusting pH to neutrality with 3.0mol/L NaOH, and absorbing 400 μL for derivatization.
Shan Biao and gradient mixing. (1) Single label. The monosaccharide controls (arabinose, mannose, glucose, galactose, galacturonic acid, glucuronic acid, fucose and rhamnose) were dissolved in ultrapure water at a concentration of 2 mmol/L. And (2) mixing. The monosaccharide controls were co-dissolved in ultrapure water so that the concentration of each standard was 1.6mg/mL, and post-dilution was a gradient mix of 6 concentrations of 1.6, 1.2, 1.0, 0.8, 0.4, 0.2 mg/mL.
Monosaccharide derivatization: 400 mu L of standard solution (Shan Biao and gradient mixed standard) and hydrolyzed polysaccharide sample are taken, 0.5mol/L PMP-methanol solution and 0.3mol/L NaOH are added into 400 mu L of the standard solution, and the mixture is uniformly mixed and reacted for 100min in a water bath at 70 ℃. Then, 500. Mu.L of 0.3mol/L HCl was added, the PMP reagent was extracted 3 times with 5mL of chloroform each time, the chloroform layer was discarded, and after centrifugation of the water layer, 1mL of the supernatant was filtered through a 0.45 μm organic filter membrane and analyzed by high performance liquid chromatography (High Performance Liquid Chromatography, HPLC).
Analysis was performed using a Waters 2984LC high performance liquid chromatograph. Chromatographic conditions: waters C18 column (4.6X105 mm,5 μm); taking acetonitrile-0.02 mol/L ammonium acetate solution (17:83) as a mobile phase chromatographic condition; column temperature is 30 ℃; the flow rate is 1.0mL/min; the detection wavelength is 250nm, and the sample injection amount is 10 mu L.
From FIGS. 6 (a) and 6 (b), the PMP pre-column derivatization method effectively separated 8 monosaccharide standards, and the retention time and peak area were brought into the standard curve to calculate the monosaccharide composition of EPS-A50, which was found to consist of Man, galA and Gal, at a molar ratio of 0.99:1.34:39.02.
example 6 extracellular polysaccharide EPS-A50 produced by Arthrobacter adenylatus in vitro binding to bile acid.
First, a bile acid stock solution is prepared: glycocholic acid (9 mmol/L), chenodeoxycholic acid (9 mmol/L), glycodeoxycholic acid (9 mmol/L), taurochenodeoxycholic acid (4.5 mmol/L), taurodeoxycholic acid (4.5 mmol/L) was dissolved in phosphate buffer solution with pH=6.8, i.e. prepared as a 36mmol/L bile acid stock solution. Stock solutions were stored in a-20 ℃ freezer and diluted to 0.72 μmol/mL bile acid working solution prior to use.
Reference is made to the scheme of Wu et al and modifications are made. 10mg/mL-110mg/mL of exopolysaccharide was placed in a 15X 150mm glass tube, 1mL of 0.01mol/L HCl was added, and acid digestion of the stomach was simulated at 37℃for 2 hours at 120 r/min. The pH of the sample was adjusted to 7-7.5 with 0.2mol/L NaOH. To each sample to be tested were added 4mL of bile acid working solution (0.72. Mu. Mol/mL) and 5mL of pancreatin (10 mg/mL in phosphate buffer at pH=6.8) and simulated in vitro intestinal digestion at 37℃at 120r/min for 2 hours. Centrifuging the mixture at 6000r/min for 20min, collecting supernatant, and storing at-20deg.C. Distilled water was used as a negative control.
And detecting the content of bile acid in the supernatant according to the determination method of the total bile acid kit. The formula of bile acid content is:
wherein, the enzyme labeling instrument (Infinite M200 PRO) reads the absorbance A0 at 405nm, and reads the absorbance A1 after 3min, wherein DeltaA=A1-A0. The ΔA measurement is the ΔA value of the sample, the ΔA calibration is the ΔA value of the calibrator, and the concentration of bile acid calibrator is 50. Mu. Mol/L.
As a result, the IC50 value of the half inhibitory concentration of EPS-A50 was 64.325mg/ml as shown in FIG. 7. Shows that EPS-A50 has potential hypolipidemic capacity and is expected to be a medicine for preventing and treating hyperlipidemia, and the strain is expected to be developed into a commercial strain.
The embodiments of the present invention have been described in detail above, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, and yet fall within the scope of the invention.
Sequence listing
<110> university of Guangxi
<120> Acinetobacter adeniveum A50 strain, extracellular polysaccharide produced and application thereof
<130> ZM211185CS
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 500
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 1
gtcttcggaa tttttatcct taacacctgt gaactattgt aattttttgc tttggtcctt 60
cggggccaga ggatttaatc aaaacctttt attattaacc tgagtctgaa aattgaaaaa 120
ttgaattatt caaaactttc aacaacggat ctcttggttc tcgcatcgat gaagaacgca 180
gcgaactgcg ataagtaatg tgaattgcag aattttgtga atcatcgaat ctttgaacgc 240
acattgcgcc ttttggtatt ccagaaggca tacctgtttg agagtcattt cttcctcaat 300
cctcggattg gtgttgactc gagcgttgcg aaacgctgag tcgaaaagaa ttggcaggca 360
ggaattcagt gctttacagt gtcttaggtt ttaccaacta cgctggccta gtaactgttt 420
tctgagctgg cctttataac agttctttta aaagtttgac ctcaaatcag gcaagactac 480
ccgctgaact taagcatatc 500
Claims (8)
1. Acidocella adephagiaBlastobotrys adeninivorans) Use of strain a50 for the preparation of a bile acid binder, characterized in thatBlastobotrys adeninivorans A50 strain is preserved in China Center for Type Culture Collection (CCTCC) at 2021, 04 and 29 days, and the preservation number is CCTCC NO: M2021485.
2. The use according to claim 1, wherein the bile acid binder is used in food or pharmaceutical products.
3. The use according to claim 1, wherein the yeast Arthrobacter adephagia is usedBlastobotrys adeninivorans A50 strain is fermented conventionally, and supernatant is taken.
4. An extracellular polysaccharide EPS-A50, which is characterized in that the extracellular polysaccharide is prepared from an adeps Zosterae MarinaeBlastobotrys adeninivorans A50 strain is fermented according to the conventional method, and supernatant fluid is taken to obtain; the saidBlastobotrys adeninivorans A50 strain is preserved in China Center for Type Culture Collection (CCTCC) at 2021, 04 and 29 days, and the preservation number is CCTCC NO: M2021485.
5. Use of the exopolysaccharide EPS-a50 according to claim 4 for the preparation of a medicament for the prophylaxis and/or treatment of hypolipidemic conditions.
6. The use according to claim 5, characterized by the use in the preparation of a medicament for the prevention and/or treatment of hyperlipidemia.
7. Acidocella adephagiaBlastobotrys adeninivorans) A50 strain, characterized in that it comprisesBlastobotrys adeninivorans A50 strain is preserved in China Center for Type Culture Collection (CCTCC) at 2021, 04 and 29 days, and the preservation number is CCTCC NO: M2021485.
8. A microbial agent comprising the yeast of Arthrobacter adephagia of claim 7Blastobotrys adeninivorans A50 strain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110881679.XA CN113801798B (en) | 2021-08-02 | 2021-08-02 | Acidocella adephagia strain A50, extracellular polysaccharide produced by same and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110881679.XA CN113801798B (en) | 2021-08-02 | 2021-08-02 | Acidocella adephagia strain A50, extracellular polysaccharide produced by same and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113801798A CN113801798A (en) | 2021-12-17 |
| CN113801798B true CN113801798B (en) | 2023-07-28 |
Family
ID=78942655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110881679.XA Active CN113801798B (en) | 2021-08-02 | 2021-08-02 | Acidocella adephagia strain A50, extracellular polysaccharide produced by same and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113801798B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101709093A (en) * | 2009-12-17 | 2010-05-19 | 广西大学 | Method for preparing blumea riparia water-soluble polysaccharides |
| CN105779297A (en) * | 2014-12-16 | 2016-07-20 | 勐海茶业有限责任公司 | Strain of Arxula adeninivorans for producing high activity polyphenoloxidase and application thereof to production of Pu'er tea |
| CN109055247A (en) * | 2018-07-13 | 2018-12-21 | 云南中茶茶业有限公司 | The method of one saccharomycete strain and its ripe general tea of processing |
| CN109385485A (en) * | 2017-08-09 | 2019-02-26 | 勐海茶业有限责任公司 | DNA bar code, primer, kit, methods and applications |
| RU205304U1 (en) * | 2021-04-12 | 2021-07-08 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Тульский государственный университет" (ТулГУ) | DEVICE FOR EXPRESS ANALYSIS OF WATER POLLUTION BY BIODEGRADABLE ORGANIC COMPOUNDS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201901007PA (en) * | 2014-08-11 | 2019-03-28 | Evolva Sa | Production of steviol glycosides in recombinant hosts |
-
2021
- 2021-08-02 CN CN202110881679.XA patent/CN113801798B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101709093A (en) * | 2009-12-17 | 2010-05-19 | 广西大学 | Method for preparing blumea riparia water-soluble polysaccharides |
| CN105779297A (en) * | 2014-12-16 | 2016-07-20 | 勐海茶业有限责任公司 | Strain of Arxula adeninivorans for producing high activity polyphenoloxidase and application thereof to production of Pu'er tea |
| CN109385485A (en) * | 2017-08-09 | 2019-02-26 | 勐海茶业有限责任公司 | DNA bar code, primer, kit, methods and applications |
| CN109055247A (en) * | 2018-07-13 | 2018-12-21 | 云南中茶茶业有限公司 | The method of one saccharomycete strain and its ripe general tea of processing |
| RU205304U1 (en) * | 2021-04-12 | 2021-07-08 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Тульский государственный университет" (ТулГУ) | DEVICE FOR EXPRESS ANALYSIS OF WATER POLLUTION BY BIODEGRADABLE ORGANIC COMPOUNDS |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113801798A (en) | 2021-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111285939B (en) | Artemisia annua polysaccharide with effects of resisting oxidation and regulating intestinal flora and preparation method and application thereof | |
| CN111961617B (en) | Multi-effect bacillus subtilis for high yield of immune polysaccharide and bacteriocin and application thereof | |
| CN111154676A (en) | Lactobacillus rhamnosus exopolysaccharide, preparation method thereof and bacteria used thereby | |
| CN110607254B (en) | Bacillus amyloliquefaciens and preparation method of extracellular polysaccharide thereof | |
| CN106520641B (en) | Bacillus amyloliquefaciens and preparation method of extracellular polysaccharide thereof | |
| CN104945527A (en) | Galactomannan antigen and preparation method thereof | |
| CN102839138B (en) | Marine bacterium pseudoalteromonas issachenkonii HZ and polysaccharide produced by same | |
| WO2023036203A1 (en) | Cs-4 fermented mycelium heteropolysaccharide, preparation method therefor and use thereof | |
| CN104231106B (en) | Paenibacillus exopolysaccharide and preparation method and application of paenibacillus exopolysaccharide | |
| CN113801798B (en) | Acidocella adephagia strain A50, extracellular polysaccharide produced by same and application thereof | |
| CN113604522B (en) | Penicillium D306 strain for producing extracellular polysaccharide and application thereof in preparation of bile acid binding agent | |
| CN111607010A (en) | Enteromorpha polysaccharide with immunoregulation activity and preparation method thereof | |
| CN105685766B (en) | Microalgae fermentation liquor exopolysaccharide, preparation method and application thereof | |
| CN103484392A (en) | Application of pseudomonas fluorescens PGM37 strain to produce glucomannan | |
| CN110305816B (en) | Streptococcus thermophilus IMAU20756 and application thereof | |
| CN113861303A (en) | Exopolysaccharide separated from lactobacillus delbrueckii and streptococcus thermophilus fermented yoghourt and application thereof | |
| AU2021104232A4 (en) | Application of sanghuangporus sanghuang fermentation broth polysaccharides in medicaments of anti-avian influenza virus | |
| CN113372463B (en) | Method for extracting probiotic functional sugar from distilled rice wine distillation residual liquid | |
| CN117180412B (en) | Acinetobacter baumannii capsular polysaccharide vaccine and preparation method thereof | |
| CN116970665B (en) | Extraction method and application of tremella aurantialba polysaccharide fermented by tremella aurantialba | |
| CN115260324B (en) | Preparation method of fingered citron polysaccharide with intestinal probiotics activity | |
| CN115948280B (en) | Amylase-producing strain R26 and application thereof | |
| CN112094751B (en) | Fermentation liquor of spirillum obliquus QYL-10, biological additive produced by fermentation liquor and application of fermentation liquor | |
| CN116445373B (en) | C clostridium perfringens toxigenic culture medium and preparation method and application thereof | |
| WO2024197693A1 (en) | Pseudoalteromonas agarivorans and method for preparing exopolysaccharide thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |